The present invention relates to compounds of formula (I):
or a pharmaceutically acceptable salt thereof. These compounds inhibit serine protease, particularly the hepatitis C virus NS3-NS4A protease.
The subject invention relates to novel P2X
3
receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X
3
receptor subunit modulator.
PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS
申请人:Shigeta Yukihiro
公开号:US20100286390A1
公开(公告)日:2010-11-11
Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.
PROTON-CONDUCTING MEMBRANE, METHOD FOR THEIR PRODUCTION AND THEIR USE IN ELECTROCHEMICAL CELLS
申请人:BASF SE
公开号:EP2804889B1
公开(公告)日:2019-03-13
Inhibitors of serine proteases
申请人:Lyons Steve
公开号:US20070105781A1
公开(公告)日:2007-05-10
This invention relates to compounds of formula I:
or a pharmaceutically acceptable salt or mixtures thereof wherein C* represents a diastereomeric carbon comprising a mixture of R and S isomers wherein the R isomer is greate than 50% of the mixture.